PHARMACEUTICAL PROJECT MANAGEMENT SOLUTIONS: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
PHARMACEUTICAL PROJECT MANAGEMENT SOLUTIONS
Largest movements
- Current investments +€658,315
up €658,315 (+411%), from €160,206 to €818,521
- Cash -€476,700
down €476,700 (-82.2%), from €579,729 to €103,029
mainly Current investments (-€658,315) and Contributions, distributions and other (-€115,000)
- Receivables within one year -€134,129
down €134,129 (-72.2%), from €185,870 to €51,740
of which Trade receivables: -€134,136
- Tangible fixed assets -€11,816
down €11,816 (-23.6%), from €50,113 to €38,297
- Reserves +€20,500
up €20,500 (+2.6%), from €780,155 to €800,655
of which Distributable reserves: +€20,500
- Other debts +€19,520
up €19,520 (+17.5%), from €111,501 to €131,021
- Gross operating margin -€5,393
down €5,393 (-2.6%), from €203,926 to €198,533
- Financial income +€3,170
up €3,170 (+45.0%), from €7,047 to €10,217
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €976,982 | €1,013,863 | +€36,880 | +3.8% |
| Fixed assets | 21/28 | €50,113 | €38,297 | -€11,816 | -23.6% |
| Tangible fixed assets | 22/27 | €50,113 | €38,297 | -€11,816 | -23.6% |
| Furniture and vehicles | 24 | €50,113 | €38,297 | -€11,816 | -23.6% |
| Current assets | 29/58 | €926,869 | €975,566 | +€48,697 | +5.3% |
| Amounts receivable within one year | 40/41 | €185,870 | €51,740 | -€134,129 | -72.2% |
| Trade receivables | 40 | €185,868 | €51,732 | -€134,136 | -72.2% |
| Other amounts receivable | 41 | €2 | €8 | +€7 | +370% |
| Current investments | 50/53 | €160,206 | €818,521 | +€658,315 | +411% |
| Cash at bank and in hand | 54/58 | €579,729 | €103,029 | -€476,700 | -82.2% |
| Deferred charges and accrued income | 490/1 | €1,065 | €2,276 | +€1,211 | +114% |
| Total equity and liabilities | 10/49 | €976,982 | €1,013,863 | +€36,880 | +3.8% |
| Equity | 10/15 | €836,010 | €856,652 | +€20,642 | +2.5% |
| Contributions | 10/11 | €18,550 | €18,550 | = | 0.0% |
| Reserves | 13 | €780,155 | €800,655 | +€20,500 | +2.6% |
| Non-distributable reserves | 130/1 | €0 | €0 | = | |
| Distributable reserves | 133 | €780,155 | €800,655 | +€20,500 | +2.6% |
| Profit (loss) carried forward | 14 | €37,305 | €37,447 | +€142 | +0.4% |
| Amounts payable | 17/49 | €140,973 | €157,210 | +€16,238 | +11.5% |
| Amounts payable within one year | 42/48 | €140,973 | €157,210 | +€16,238 | +11.5% |
| Trade debts | 44 | €0 | €2,426 | +€2,426 | |
| Suppliers | 440/4 | €0 | €2,426 | +€2,426 | |
| Taxes, remuneration and social security | 45 | €29,471 | €23,763 | -€5,708 | -19.4% |
| Taxes | 450/3 | €29,471 | €23,763 | -€5,708 | -19.4% |
| Other amounts payable | 47/48 | €111,501 | €131,021 | +€19,520 | +17.5% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €13,989 | €13,840 | -€149 | -1.1% |
| Other operating charges | 640/8 | €434 | €1,479 | +€1,044 | +240% |
| Gross operating margin | 9900 | €203,926 | €198,533 | -€5,393 | -2.6% |
| Operating profit (loss) | 9901 | €189,502 | €183,214 | -€6,288 | -3.3% |
| Financial income | 75/76B | €7,047 | €10,217 | +€3,170 | +45.0% |
| Recurring financial income | 75 | €7,047 | €10,217 | +€3,170 | +45.0% |
| Financial charges | 65/66B | €170 | €78 | -€93 | -54.4% |
| Recurring financial charges | 65 | €170 | €78 | -€93 | -54.4% |
| Profit (loss) for the period before taxes | 9903 | €196,378 | €193,353 | -€3,026 | -1.5% |
| Income taxes | 67/77 | €56,472 | €57,710 | +€1,238 | +2.2% |
| Profit (loss) for the period | 9904 | €139,906 | €135,642 | -€4,264 | -3.0% |
| Profit (loss) for the period to be appropriated | 9905 | €139,906 | €135,642 | -€4,264 | -3.0% |
Source: filed annual accounts (NBB), financial years ended 30 June 2024 and 30 June 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 24 October 2026 via checked.be.